From: Positive prognostic value of HER2-HER3 co-expression and p-mTOR in gastric cancer patients
 | Total patients | HER2-positive | HER2-negative | P value | HER3-positive | HER3-negative | P value | HER2/HER3 co-expression | P value | |
---|---|---|---|---|---|---|---|---|---|---|
Sex | Male | 80 | 19 | 61 | 0.88 | 42 | 38 | 0.60 | 16 | 0.75 |
Female | 40 | 10 | 30 | Â | 23 | 17 | Â | 9 | Â | |
Age | <60y | 49 | 9 | 40 | 0.02 | 24 | 25 | 0.34 | 7 | 0.14 |
>60y | 71 | 20 | 51 | Â | 41 | 30 | Â | 18 | Â | |
Tumor size | <3Â cm | 15 | 4 | 11 | 1.00 | 7 | 8 | 0.53 | 4 | 0.80 |
>3Â cm | 105 | 25 | 80 | Â | 58 | 47 | Â | 21 | Â | |
Differentiation | Well/moderate | 102 | 20 | 82 | 0.01 | 52 | 50 | 0.10 | 17 | 0.02 |
Poor | 18 | 9 | 9 | Â | 13 | 5 | Â | 8 | Â | |
Tumor location | Upper/Medium | 77 | 17 | 60 | 0.47 | 42 | 35 | 0.91 | 16 | 0.98 |
Low | 43 | 12 | 31 | Â | 23 | 20 | Â | 9 | Â | |
Depth of invasion | T1 + T2 | 22 | 4 | 18 | 0.47 | 7 | 15 | 0.02 | 2 | 0.23 |
T3 + T4 | 98 | 25 | 73 |  | 58 | 40 |  | 23 |  | |
Lymph node metastasis | N0 | 25 | 6 | 19 | 0.98 | 11 | 14 | 0.25 | 6 | 0.59 |
N1 + N2 + N3 | 95 | 23 | 72 |  | 54 | 41 |  | 19 |  | |
Metastasis | M0 | 114 | 25 | 89 | 0.045 | 62 | 52 | 1.00 | 23 | 0.80 |
M1 | 6 | 4 | 2 | Â | 3 | 3 | Â | 2 | Â | |
TNM stage | I + II | 33 | 5 | 28 | 0.16 | 17 | 16 | 0.72 | 5 | 0.35 |
III + IV | 87 | 24 | 63 |  | 48 | 39 |  | 20 |  |